©The Author(s) 2018. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Gastroenterol. Feb 21, 2018; 24(7): 767-774
Published online Feb 21, 2018. doi: 10.3748/wjg.v24.i7.767
Published online Feb 21, 2018. doi: 10.3748/wjg.v24.i7.767
Epidemiology, determinants, and management of AIDS cholangiopathy: A review
Maliha Naseer, Francis E Dailey, Alhareth Al Juboori, Sami Samiullah, Veysel Tahan, Division of Gastroenterology and Hepatology, Department of Internal Medicine, University of Missouri, Columbia, MO 65212, United States
Author contributions: All authors equally contributed to this paper with conception and design of the study, literature review and analysis, drafting and critical revision and editing, and final approval of the final version.
Conflict-of-interest statement: No potential conflicts of interest.
Correspondence to: Veysel Tahan, MD, FACP, FACG, FESBGH, Assistant Professor of Clinical Medicine, Division of Gastroenterology and Hepatology, Department of Internal Medicine, University of Missouri, 1 Hospital Drive, Columbia, MO 65212, United States. tahanv@health.missouri.edu
Telephone: +1-573-8846044 Fax: +1-573-8844595
Received: December 25, 2017
Peer-review started: December 25, 2017
First decision: January 4, 2018
Revised: January 24, 2018
Accepted: February 1, 2018
Article in press: February 1, 2018
Published online: February 21, 2018
Processing time: 46 Days and 8.6 Hours
Peer-review started: December 25, 2017
First decision: January 4, 2018
Revised: January 24, 2018
Accepted: February 1, 2018
Article in press: February 1, 2018
Published online: February 21, 2018
Processing time: 46 Days and 8.6 Hours
Core Tip
Core tip: Though a declining phenomenon in the Western world, acquired immunodeficiency syndrome (AIDS)-related cholangiopathy has been shown to cause significant burden and remains an important etiology of hepatobiliary pathology in those affected with human immunodeficiency virus (HIV). While it is linked to advanced immunosuppression in AIDS patients, particularly in those with extremely low CD4 counts and opportunistic infections, as well as those with drug-resistant HIV infection, it is also seen in developing countries due to less available anti-retroviral therapy, decreased awareness, and medication non-compliance.